Article Text

Download PDFPDF
Raloxifene produced both harms and benefits in postmenopausal women, with no reduction in cardiovascular disease risk

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

 Q In postmenopausal women, does raloxifene reduce the risks of coronary events and invasive breast cancer?

Clinical impact ratings GP/FP/Primary care ★★★★★★☆ Internal medicine ★★★★★★☆ Cardiology ★★★★★★☆ Geriatrics ★★★★★★☆ Haematology ★★★★★★☆ Oncology ★★★★★★☆ Rheumatology ★★★★★★☆ Gynaecology ★★★★★★☆ Endocrine ★★★★★☆☆


Embedded ImageDesign:

randomised placebo controlled trial (Raloxifene Use for The Heart [RUTH] trial).

Embedded ImageAllocation:


Embedded ImageBlinding:

blinded (clinicians, participants, outcome assessors, laboratory staff, and sponsor).*

Embedded ImageFollow up period:

median 5.6 years.

Embedded ImageSetting:

177 centres in 26 countries worldwide.

Embedded ImageParticipants:

10 101 postmenopausal women ⩾55 years of age (mean 68 y) with or at increased risk of coronary heart disease. Exclusion criteria included recent myocardial infarction (MI) or revascularisation procedure; history of cancer, venous thromboembolism (VTE), heart failure, or chronic liver or renal disease; life expectancy <5 …

View Full Text


  • * See glossary.

  • For correspondence: Dr E Barrett-Connor, University of California, San Diego, La Jolla, CA, USA. ebarrettconnor{at}

  • Source of funding: Eli Lilly.

Linked Articles

  • Glossary
    BMJ Publishing Group Ltd